Cardiff Oncology Stock Probability Of Bankruptcy
| XE7C Stock | EUR 3.91 0.10 2.49% |
Cardiff |
Cardiff Oncology Company chance of financial distress Analysis
Cardiff Oncology's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Cardiff Oncology Probability Of Bankruptcy | Over 51% |
Most of Cardiff Oncology's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cardiff Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Cardiff Oncology probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Cardiff Oncology odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Cardiff Oncology financial health.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, Cardiff Oncology has a Probability Of Bankruptcy of 51%. This is 17.81% higher than that of the Healthcare sector and 7.0% lower than that of the Biotechnology industry. The probability of bankruptcy for all Germany stocks is 28.04% lower than that of the firm.
Cardiff Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cardiff Oncology's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cardiff Oncology could also be used in its relative valuation, which is a method of valuing Cardiff Oncology by comparing valuation metrics of similar companies.Cardiff Oncology is currently under evaluation in probability of bankruptcy category among related companies.
Cardiff Fundamentals
| Return On Equity | -0.32 | |||
| Return On Asset | -0.19 | |||
| Operating Margin | (102.39) % | |||
| Current Valuation | (45.06 M) | |||
| Shares Outstanding | 44.68 M | |||
| Shares Owned By Insiders | 7.30 % | |||
| Shares Owned By Institutions | 23.02 % | |||
| Price To Book | 0.57 X | |||
| Price To Sales | 147.11 X | |||
| Revenue | 359 K | |||
| Gross Profit | (17.02 M) | |||
| EBITDA | (27.84 M) | |||
| Net Income | (28.29 M) | |||
| Cash And Equivalents | 140.05 M | |||
| Cash Per Share | 3.54 X | |||
| Total Debt | 408 K | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 31.20 X | |||
| Book Value Per Share | 2.61 X | |||
| Cash Flow From Operations | (23.04 M) | |||
| Earnings Per Share | (0.81) X | |||
| Target Price | 25.33 | |||
| Number Of Employees | 22 | |||
| Beta | 1.66 | |||
| Market Capitalization | 77.48 M | |||
| Total Asset | 149.54 M | |||
| Net Asset | 149.54 M |
About Cardiff Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cardiff Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cardiff Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cardiff Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cardiff Oncology is a strong investment it is important to analyze Cardiff Oncology's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cardiff Oncology's future performance. For an informed investment choice regarding Cardiff Stock, refer to the following important reports:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Cardiff Oncology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.Note that the Cardiff Oncology information on this page should be used as a complementary analysis to other Cardiff Oncology's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Complementary Tools for Cardiff Stock analysis
When running Cardiff Oncology's price analysis, check to measure Cardiff Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardiff Oncology is operating at the current time. Most of Cardiff Oncology's value examination focuses on studying past and present price action to predict the probability of Cardiff Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardiff Oncology's price. Additionally, you may evaluate how the addition of Cardiff Oncology to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |